PAPR

North American Respiratory PPE Market Study 2023: Cloud Computing and Data Analytics with SCBA and PAPR Products will Drive Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Health, Other Manufacturing, Manufacturing, Medical Devices, Cloud computing, Carbon, Scott Air-Pak SCBA, Traction, American Respiratory Care Foundation, PAPR, Disposable product, Safety, Employment, PPE, SCBA, Personal protective equipment

The "North American Respiratory PPE Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North American Respiratory PPE Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The surge in innovation and the integration of cutting-edge technologies, such as cloud computing and data analytics, with SCBA and PAPR product categories will drive market growth during the forecast period.
  • The United States accounted for the largest revenue share in the North American respiratory PPE market in 2022.
  • Favorable safety regulations and improvements in PPE testing standards will continue to ensure the quality and safety of products for end users.

Keysight Introduces New Method to Accelerate Power Amplifier Digital Pre-Distortion Test Speeds

Retrieved on: 
Thursday, March 9, 2023
Data Management, Consumer Electronics, Technology, Semiconductor, Telecommunications, Software, Networks, Internet, 5G, Hardware, Electronic Design Automation, Gallium arsenide, DPD, Digital, Iterative learning control, Communication, NYSE, Fabless manufacturing, PAPR, PXA, Multidimensional Digital Pre-distortion, High frequency, Performance, PAE, ILC, Wireless, SLM Solutions Group AG, R, Transformer, Medical imaging

Keysight Technologies, Inc. (NYSE: KEYS) introduces the new Iterative Learning Control (ILC) test method that significantly shortens Digital Pre-Distortion (DPD) test times for power amplifiers.

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS) introduces the new Iterative Learning Control (ILC) test method that significantly shortens Digital Pre-Distortion (DPD) test times for power amplifiers.
  • By shortening the time it takes to complete the design and validation process, power amplifier manufacturers are able to accelerate their time-to-market.
  • Keysight meets this need by introducing the innovative ILC DPD test method that shortens DPD test time to minutes and accelerates R&D time from test validation to product design and optimization.
  • The ILC DPD test method offers the following benefits:
    Faster Test Speeds – Optimizes the N9055EM0E software to reduce the characterization of power amplifiers to minutes.

Korea Maritime and Ocean University Scientists Develop Pulse Position Modulation for Low-power Consuming Information Decoding and Enhanced Power Transfer Performance

Retrieved on: 
Thursday, December 1, 2022
Transfer, Korea Maritime and Ocean University, Growth, Architecture, Internet, Communication, Radio, Literature, PPM, LNA, Module (mathematics), International Journal of Wireless Information Networks, IOT, Motivation, Pulse, PAPR, Research, Ecosystem, RF, Integrated receiver/decoder, WPT, IEEE, Mobile phone, Television

BUSAN, South Korea, Dec. 1, 2022 /PRNewswire/ -- Simultaneous wireless information and power transfer (SWIPT) is a promising technology to connect and energize low-power devices wirelessly over a long distance. The radio frequency-based technique would thus enable the Internet of Things in the future. However, state-of-the-art low-power SWIPT receivers still consume much more energy for communication than the amount they can harvest, which hinders further development and growth of the Internet-of-Things (IoT) ecosystem.

Key Points: 
  • Recently, Dr. Junghoon Kim of the Korea Maritime and Ocean University and his colleague, have proposed a novel signal design for SWIPT with IntRx architecture.
  • To begin with, they modified a conventional pulse position modulation scheme (M-PPM) to make it suitable for SWIPT IntRx.
  • To sum up, the comprehensive research confirms the feasibility and outstanding performance of the new modulation method, whichcan improve power transfer efficiency and reduce power consumption for information decoding.
  • Title of original paper:Wireless Information and Power Transfer for IoT: Pulse Position Modulation, Integrated Receiver, and Experimental Validation

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

Retrieved on: 
Tuesday, November 29, 2022
Empathy, Learning, Risk, Data, Protein, Journal, PAPR, Journal of Medical Economics, SALT, Intellectual disability, MS, Blood, Policy, Patient, Arm, Sumathi Best Television Current Reporting Award, Cerebral palsy, Health, Seizure, FDA, COVID-19, Private, Preterm birth, Work, Physician, Mortality, Risk assessment, Premature, Behavior, Pregnancy, Mother, Test, Hearing loss, SPTB, Health equity, Disease, Prospectus, CPT, Death, Infant, Woman, Birth control, Risk management, MD

SALT LAKE CITY and ARLINGTON, Va., Nov. 29, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Fors Marsh, a company dedicated to solving complex challenges through market research, are collaborating to provide Sera's PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023.

Key Points: 
  • We are encouraged by the PreTRM Test's ability to help reduce the negative health and cost outcomes associated with preterm birth."
  • "By providing the PreTRM Test to employees, Fors Marsh is illustrating its strong commitment to the well-being of women and their children," said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics.
  • Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarksorregisteredtrademarksofSeraPrognostics,Inc.in theUnited Statesand/orother countries.
  • This press release contains "forward-looking statements" within the meaning of the Private SecuritiesLitigationReformActof1995,includingstatementsrelatingtoFors Marsh's inclusion of the PreTRM test in its employee maternity benefits package; and the company's strategic directives under the caption "About SeraPrognostics,Inc.

BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS

Retrieved on: 
Thursday, September 22, 2022
PAPR, Premature, Medicare, Blood, Sumathi Best Television Current Reporting Award, Banner Health, Patient, U.S. Securities and Exchange Commission, Physician, UHP, NASDAQ, Research, Rehabilitation, Prospectus, Death, Risk, Outcomes research, Preterm birth, COVID-19, SALT, Birth certificate, Company, Learning, Banner, ClinicoEconomics and Outcomes Research, Medicaid, Disease, Insurance, CPT, Mortality, Cerebral palsy, Mother, Seizure, Woman, FDA, Hearing loss, Partnership, Pregnancy, CEO, Commercial, Security (finance), SPTB, Health, Intellectual disability, List, Biomarker, Private Securities Litigation Reform Act, Risk assessment, MS, Test, Protein, Form, Birth control, Health insurance, Medical device, Hospital, PHOENIX, MD

SALT LAKE CITY and PHOENIX, Sept. 22, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Banner Health today announced that Sera's PreTRM® Test will be available to Banner – University Family Care/ AHCCCS Complete Care (B – UFC/ACC) members. The PreTRM® Test is the only broadly clinically validated, commercially available blood test that provides an early, individual risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies.

Key Points: 
  • "We are very pleased to work with Banner Health, which shares our commitment to reducing the adverse consequences of preterm birth.
  • "A growing body of evidence supports the potential for the PreTRM Test to improve fetal-maternal health outcomes and reduce the costs associated with premature birth.
  • Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care.
  • www.pretrm.com
    Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. inthe United Statesand/or other countries.

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

Retrieved on: 
Tuesday, August 23, 2022
Safety, NYSE, Nighthawk, HVAC, Form 10-K, Anthrax, Therapy, Life, Vaccine, Doctor of Philosophy, Time, Sale, Maintenance, Toxin (comics), SEC, HEPA, Infection, PAPR, Triangle Park (Quezon City), CDMO, GLOBE, Classification, Company, Immune system, Population, DOD, Twitter, Terminology, Marketing, Tularemia, Ecosystem, Annual report, Private Securities Litigation Reform Act, Growth, Drug development, Acquisition, Monkeypox, Elusys Therapeutics, Research

The buildout of this facility follows our acquisition of biodefense company Elusys Therapeutics and represents the next stage in our efforts to develop medical countermeasures to protect the population against emerging biothreats.

Key Points: 
  • The buildout of this facility follows our acquisition of biodefense company Elusys Therapeutics and represents the next stage in our efforts to develop medical countermeasures to protect the population against emerging biothreats.
  • Matthew M. Seavey, PhD, Vice President of Research of NightHawk commented, This new BSL-2 facility is being designed to accommodate research on high-priority infectious agents.
  • NightHawk Biosciences is a fully-integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization.
  • For more information on the Company and is subsidiaries, please visit: www.nighthawkbio.com , and also follow us on Twitter .

AirBoss Announces 2nd Quarter Results and Continued Strength in Its Opportunity Pipeline

Retrieved on: 
Thursday, August 4, 2022
SUV, International Financial Reporting Standards, Natural rubber, OEM, NIOSH, Technology, Growth, Investment, TSX, Office of Inspector General, U.S. Department of Health and Human Services, Traction, Board, Original equipment manufacturer, Research, Workforce, Adjustment, ACE inhibitor, Income, Health, Public expenditure, Powered air-purifying respirator, EBITDA, Solution, Plastech Engineered Products, COVID-19, Company, U.S. Department of Defense Strategy for Operating in Cyberspace, Mission statement, PAPR, International, Acquisition, Depreciation, TTM, IFRS, AEP, BOS, Color, PPE, Engineering, ADG, Rubber industry in Malaysia, HHS, OTCQX, Renewable energy, Medical device, Fine chemical, Retail, Risk management, AirBoss of America

Gross profit as a percentage of net sales decreased to 18.2% for 2022 year-to-date compared with 26.2% for 2021 year-to-date.

Key Points: 
  • Gross profit as a percentage of net sales decreased to 18.2% for 2022 year-to-date compared with 26.2% for 2021 year-to-date.
  • In both cases, the decreases were primarily the result of delivery of PAPRs and nitrile gloves to HHS in 2021.
  • Gross profit at AirBoss Defense Group decreased by 61.2% to $9,754 for the quarter and by 18.7% to $37,425 year-to-date, from the comparable periods in 2021.
  • Despite these evolving global challenges, AirBoss continues to focus on opportunities in AirBoss Defense Groups (ADG) opportunity pipeline, with strong traction for the quarter in at AirBoss Rubber Solutions (ARS) and continued diligent work to address the related impacts to AirBoss Engineered Products (AEP).

ILC Dover Announces European Launch of Sentinel Clear XE™ PAPR

Retrieved on: 
Thursday, July 21, 2022
Sentinel, Motion, CEO, PAPR, PPE, ILC Dover, Solution, Personal protective equipment, Facial recognition, Safety, COVID-19, XE, Certification, Company, Efficiency, Communication, API, Growth, Fine chemical

NEWARK, Del., July 21, 2022 /PRNewswire/ -- ILC Dover Inc., specializing in innovative single-use solutions for global biotherapeutics and pharmaceutical processing as well as personal protective equipment (PPE), announced the European launch of the Sentinel Clear XE™ powered air purifying respirator (PAPR). The system, built upon the success of the Sentinel XT™ Clear model sold in North America, is ideal for protecting workers in pharmaceutical manufacturing operations from exposure to toxic airborne particles.

Key Points: 
  • The Sentinel Clear XE PAPR's features include:
    Best in class protection.
  • The Sentinel Clear XE PAPR offers TH3 protection, the highest level possible under EN 12941 certification.
  • "The Sentinel Clear XE PAPR is a game-changer for operators processing active pharmaceutical ingredients (API's) and we are glad that our customers in Europe will now have access to this innovative system," said Corey Walker, CEO of ILC Dover.
  • For more information on Sentinel Clear XE PAPR, please visit our website or contact your local sales representative.

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE

Retrieved on: 
Thursday, May 19, 2022
Physician, CPT, Death, Risk, Form, Company, Blood, Private Securities Litigation Reform Act, Seizure, Disease, U.S. Securities and Exchange Commission, Journal, Proteomics, PAPR, Patient, Woman, Hearing loss, NASDAQ, Health, Prospectus, Sumathi Best Television Current Reporting Award, Cerebral palsy, Premature, COVID-19, Mortality, Trial of the century, Gestational age, FDA, SALT, MS, Pregnancy, Learning, Biomarker, Medicine, Spontaneous, ACOG, Preterm birth, Protein, Security (finance), United, Intellectual disability, CEO, Birth control, Health insurance, Risk management, MD

SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of improved PreTRM® test performance using women from the Proteomic Assessment of Preterm Risk (PAPR) clinical study whose pregnancy outcomes are aligned with updated ACOG gestational age dating guidelines. The newly published article reports:

Key Points: 
  • "A PreTRM test higher risk result reflects a similar risk as is revealed by traditional assessment techniques, but the PreTRM test identifies far more patients who are at risk of premature delivery.
  • The PreTRM test was developed and validated for prediction of spontaneous preterm birth broadly in the U.S. in the Proteomic Assessment of Preterm Risk (PAPR) study.
  • Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care.
  • Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc.in the United Statesand/or other countries.

SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT

Retrieved on: 
Thursday, May 5, 2022
Every Mother Counts (album), SALT, Biomarker, United Nations, Seizure, Risk, Death, Learning, CEO, Disease, Preterm birth, Mortality, Woman, NASDAQ, Newborn Foundation, Company, Premature, CPT, Patient, Partnership, Hearing loss, FDA, Industry, Gestational age, Research, Child, Infant, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Pregnancy, Policy, Physician, Cerebral palsy, Security (finance), Prospectus, Foundation, SPTB, Sumathi Best Television Current Reporting Award, Public health, Education, PAPR, Protein, COVID-19, Goal, Global health, Health equity, Foundation (nonprofit), MS, Form, Blood, Health, Intellectual disability, Birth control, Pharmaceutical industry, Risk management, MD

SALT LAKE CITY, May 5, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and the Newborn Foundation today announced the launch of the Every Mother, Every Baby Project.

Key Points: 
  • "Biomarker tests that identify women at risk of preterm birth and enable risk-reduction interventions are essential for reducing neonatal mortality and improving outcomes.
  • The Every Mother, Every Baby Project is designed to achieve three key objectives:
    Reduce maternal and newborn mortality through mitigation of risks associated with unanticipated preterm birth.
  • "The Newborn Foundation is a recognized leader in its work to improve newborn and infant health, both in the United States and around the world.
  • Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc in the U.S. and/or other countries.